Type 1 diabetes (autoantibody positive).
Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors within 6 months
Known severe heart failure, classified as NYHA 4.
Active myocarditis; malfunctioning artificial heart valve.
History of ventricular tachycardia within 3 months before study entry; second- or third-degree atrioventricular block.
Supine systolic blood pressure <85 mm Hg or >200 mm Hg at screening.
Primary renal impairment, creatinine clearance < 45 ml/min if treated with metformin.
Uncorrected hypokalemia or hyperkalemia (potassium <3.5 mmol/l or >5.5 mmol/l).
Significant anemia (Hb < 90 g/l)
Severe gastrointestinal disease, including gastroparesis. As judged by the Investigator.
Body mass index (BMI) > 45 kg/m2.
Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.
Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant.
Current drug and alcohol abuse.
History of acute or chronic pancreatitis
Subjects considered by the Investigator to be unsuitable for the study.

NCT02621489_exc_T1
Condition
Type 1 diabetes
NCT02621489_exc_T2
Measurement
autoantibody
NCT02621489_exc_T3
Value
positive
NCT02621489_exc_T4
Drug
GLP-1 analogues
NCT02621489_exc_T5
Drug
dipeptidyl peptidase inhibitors
NCT02621489_exc_T6
Scope
GLP-1 analogues or dipeptidyl peptidase inhibitors
NCT02621489_exc_T7
Temporal
within 6 months
NCT02621489_exc_T8
Condition
heart failure
NCT02621489_exc_T9
Qualifier
severe
NCT02621489_exc_T10
Measurement
NYHA
NCT02621489_exc_T11
Value
4
NCT02621489_exc_T12
Condition
Active myocarditis
NCT02621489_exc_T13
Device
artificial heart valve
NCT02621489_exc_T14
Qualifier
malfunctioning
NCT02621489_exc_T15
Condition
ventricular tachycardia
NCT02621489_exc_T16
Temporal
within 3 months
NCT02621489_exc_T17
Condition
third-degree atrioventricular block
NCT02621489_exc_T18
Condition
nd- or ee atrioventricular block.
Su
NCT02621489_exc_T19
Measurement
systolic blood pressure
NCT02621489_exc_T20
Qualifier
Supine
NCT02621489_exc_T21
Value
<85 mm Hg
NCT02621489_exc_T22
Value
>200 mm Hg
NCT02621489_exc_T23
Scope
<85 mm Hg or >200 mm Hg
NCT02621489_exc_T24
Condition
Primary renal impairment
NCT02621489_exc_T25
Measurement
creatinine clearance
NCT02621489_exc_T26
Value
< 45 ml/min
NCT02621489_exc_T27
Drug
metformin
NCT02621489_exc_T28
Condition
hypokalemia
NCT02621489_exc_T29
Condition
hyperkalemia
NCT02621489_exc_T30
Measurement
potassium
NCT02621489_exc_T31
Value
<3.5 mmol/l
NCT02621489_exc_T32
Value
>5.5 mmol/l
NCT02621489_exc_T33
Scope
<3.5 mmol/l or >5.5 mmol/l
NCT02621489_exc_T34
Scope
hypokalemia or hyperkalemia
NCT02621489_exc_T35
Condition
anemia
NCT02621489_exc_T36
Qualifier
Significant
NCT02621489_exc_T37
Measurement
Hb
NCT02621489_exc_T38
Value
< 90 g/l
NCT02621489_exc_T39
Condition
gastrointestinal disease
NCT02621489_exc_T40
Qualifier
Severe
NCT02621489_exc_T41
Condition
gastroparesis
NCT02621489_exc_T42
Measurement
Body mass index
NCT02621489_exc_T43
Measurement
BMI
NCT02621489_exc_T44
Value
> 45 kg/m2
NCT02621489_exc_T45
Condition
Malignant neoplasm
NCT02621489_exc_T46
Procedure
chemotherapy
NCT02621489_exc_T47
Procedure
surgery
NCT02621489_exc_T48
Procedure
radiation
NCT02621489_exc_T49
Procedure
palliative therapy
NCT02621489_exc_T50
Temporal
previous 5 years.
NCT02621489_exc_T51
Scope
chemotherapy, surgery, radiation or palliative therapy
NCT02621489_exc_T52
Negation
allowed
NCT02621489_exc_T53
Condition
intraepithelial squamous cell carcinoma
NCT02621489_exc_T54
Qualifier
skin
NCT02621489_exc_T55
Drug
topical 5FU
NCT02621489_exc_T56
Condition
basal cell skin cancer
NCT02621489_exc_T57
Scope
intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer
NCT02621489_exc_T59
Condition
alcohol abuse
NCT02621489_exc_T60
Condition
hol y of
NCT02621489_exc_T61
Condition
ic pa ubjects cons
NCT02621489_exc_T62
Condition
chronic pancreatitis